Table 1.

Incidence rates and adjusted hazard ratios for future cardiovascular events and all-cause mortality associated with baseline interleukin-6 levels in the Cardiovascular Inflammation Reduction Trial

	Interleukin-6 (baseline)				Multivariable-adjusted risk (per quartile)
IL-6 (pg/mL)	Quartile 1a ≤1.69	Quartile 2a 1.70–2.50	Quartile 3a 2.51–3.86	Quartile 4a ≥3.87	Excluding lipidsa	Including lipidsb
MACE-plus
IR (N)	2.28 (53)	4.12 (90)	4.66 (96)	5.30 (102)	—	—
HR	1.0	1.66	1.92	2.11	1.24	1.20
95% CI	—	1.18–2.35	1.36–2.70	1.49–2.99	1.12–1.38	1.08–1.33
P	—	0.004	0.0002	<0.0001	<0.0001	0.0008
MACE
IR (N)	1.70 (40)	3.29 (73)	3.78 (79)	4.62 (90)	—	—
HR	1.0	1.72	2.01	2.35	1.28	1.23
95% CI	—	1.16–2.54	1.36–2.96	1.59–3.47	1.14–1.44	1.10–1.38
P	—	0.007	0.0004	<0.0001	<0.0001	0.0005
Myocardial infarction
IR (N)	1.31 (31)	2.15 (48)	2.33 (49)	2.95 (58)	—	—
HR	1.0	1.49	1.67	2.08	1.25	1.20
95% CI	—	0.94–2.35	1.05–2.64	1.32–3.29	1.09–1.43	1.04–1.38
P	—	0.09	0.03	0.002	0.002	0.01
Stroke
IR (N)	0.29 (7)	0.61 (14)	0.65 (14)	0.94 (19)	—	—
HR	1.0	1.83	1.88	2.35	1.26	1.17
95% CI	—	0.73–4.57	0.75–4.73	0.95–5.80	0.97–1.63	0.90–1.53
P	—	0.20	0.18	0.06	0.08	0.24
All-cause mortality
IR (N)	0.47 (12)	1.50 (36)	2.47 (56)	2.31 (50)	—	—
HR	1.0	2.54	4.14	3.55	1.39	1.35
95% CI	—	1.31–4.90	2.21–7.77	1.85–6.78	1.19–1.63	1.15–1.59
P	—	0.006	<0.0001	0.0001	<0.0001	0.0002

CI, confidence interval; HR, hazard ratio; IR, incidence rate (per 100 person-years); MACE, major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); MACE-plus, MACE plus hospitalization for unstable angina requiring urgent revascularization.

^aAdjusted for age, gender, smoking status, body mass index, and blood pressure and stratified on diabetes and or metabolic syndrome.

^bAdditionally adjusted for total cholesterol and high-density lipoprotein cholesterol.